we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day ...

One of the first EGFR inhibitors in the clinic is gefitinib (Iressa®), a small-molecule tyrosine-kinase inhibitor (TKI). Following four phase I studies, two large phase II trials (IDEAL I and II ...

In this open-label, phase III study, patients were randomly assigned to 250 mg per day gefitinib or a carboplatin–paclitaxel combination. Progression-free survival (PFS) at 12 months was 24.9% ...

1 In this study, 1,217 Asian non-smokers or former light smokers with lung adenocarcinoma were randomly assigned to receive gefitinib (250 mg orally, daily) until progression or carboplatin (AUC ...